SOPHiA GENETICS (SOPH) CSO Kevin Puylaert reports initial holdings

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported his initial ownership on a Form 3. He directly holds 92,419 ordinary shares, including 30,405 shares issuable upon settlement of five restricted stock unit grants that vest over time with continued service.

He also holds several vested and unvested share options to buy ordinary shares at exercise prices ranging from 3.29 to 18.00, with expiration dates from 2029 through 2035. These option and RSU awards reflect his equity-based compensation and align part of his pay with the company’s share performance.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Puylaert Kevin

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Sales Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	92,419(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(2)	02/08/2029	Ordinary Shares	10,000	$4	D
Share Option (Right to Buy)	(2)	06/25/2030	Ordinary Shares	15,000	$4.21	D
Share Option (Right to Buy)	(2)	01/28/2031	Ordinary Shares	20,000	$6.31	D
Share Option (Right to Buy)	(2)	07/22/2031	Ordinary Shares	32,264	$18	D
Share Option (Right to Buy)	(3)	03/30/2032	Ordinary Shares	10,191	$8.36	D
Share Option (Right to Buy)	(4)	04/03/2033	Ordinary Shares	12,968	$4.72	D
Share Option (Right to Buy)	(2)	11/21/2033	Ordinary Shares	5,921	$3.86	D
Share Option (Right to Buy)	(5)	04/02/2034	Ordinary Shares	57,165	$4.96	D
Share Option (Right to Buy)	(6)	04/02/2035	Ordinary Shares	28,409	$3.29	D

Explanation of Responses:

1. Includes 30,405 ordinary shares issuable upon settlement of five restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 40 ordinary shares from a March 30, 2022 grant vesting in equal monthly installments through March 30, 2026; (ii) 1,156 ordinary shares from May 18, 2022 grant vesting in equal quarterly installments through May 18, 2026; (iii) 2,640 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iv) 7,279 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (v)19,290 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.

2. The share options are fully vested and exercisable.

3. The share option vests and becomes exercisable as to 25% of the ordinary shares on March 30, 2023, and then in equal monthly installments through March 30, 2026.

4. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.

5. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.

6. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney

	/s/ Elimara Brunetto as Attorney-in-fact for Kevin Puylaert	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Kevin Puylaert’s Form 3 show for SOPHiA GENETICS (SOPH)?

The Form 3 shows Kevin Puylaert’s initial equity ownership in SOPHiA GENETICS SA. He reports 92,419 ordinary shares held directly, plus multiple option and restricted stock unit awards that can convert into additional ordinary shares if vesting and exercise conditions are satisfied.

How many SOPHiA GENETICS ordinary shares does Kevin Puylaert directly hold?

Kevin Puylaert directly holds 92,419 ordinary shares of SOPHiA GENETICS SA. This figure includes shares already issued in his name as well as 30,405 additional ordinary shares that are issuable upon settlement of various restricted stock unit grants, subject to vesting schedules.

What restricted stock units (RSUs) are reported for SOPHiA GENETICS CSO Kevin Puylaert?

The filing notes 30,405 ordinary shares issuable from five RSU grants. Each RSU represents one ordinary share, with tranches vesting in monthly or quarterly installments from March 2022 through April 2028, assuming Kevin Puylaert continues his service with SOPHiA GENETICS SA.

What share options does Kevin Puylaert hold in SOPHiA GENETICS?

Kevin Puylaert holds several share options to buy SOPHiA GENETICS ordinary shares. These options have exercise prices between 3.29 and 18.00 and expiration dates from 2029 to 2035, with some already fully vested and others vesting over time according to specified schedules.

Are Kevin Puylaert’s SOPHiA GENETICS share options vested?

Some of Kevin Puylaert’s share options are fully vested while others vest over time. One footnote states certain options are fully vested and exercisable, while additional option grants vest in installments through dates ranging from March 2026 to April 2028, subject to continued service.